The Code of Conduct Edition 19 is being reviewed in 2024.

The purpose of the 2024 Code Review is to ensure the Code remains relevant, coherent, useful, and credible to members, the wider industry, and external stakeholders.

Reviewing Code Edition 19 will build on the work undertaken by the last Code Review. The shift towards a principles-based Code has been welcomed by members and this Review provides an opportunity to take stock of the Code and make improvements should they be identified.

Consultation window is now closed.

This consultation period ran between April 2nd – May 2nd 2024.

This Consultation Paper explains the objectives, review timeframe and methodology of the review. It also highlights seven key topics to which we welcome comments. These are topics where our stakeholders are likely to have a view and are worthy of discussion. These are not the only topics that will be considered as part of the Code review.

Who provided feedback?

We received over 50 written submissions during this consultation period. Feedback was received by members, non-member pharmaceutical companies, individuals, the patient community, individuals and the healthcare professional community, as well as other stakeholders with an interest in the Code. 

Still want to have your say?

Please reach out to Medicines Australia via email

An overview of the review process and timeline.

The Code Review is a consultative process involving Medicines Australia’s decision-making bodies, the Code Compliance Network, the patient community, members, and external stakeholders.

Expert guidance is being provided by a Code Review Working Group made up of members.

Should the review find any updates are needed, they will be put forward for formal adoption by special resolution at the Medicines Australia Annual General Meeting in October 2024. 

Please get in touch with the MA Ethics & Compliance Team if you have any questions via email or (02) 6147 6500.